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The use of inhaled glucocorticoids for persistent asthma causes a temporary reduction
in growth velocity in prepubertal children. The resulting decrease in attained height
1 to 4 years after the initiation of inhaled glucocorticoids is thought not to decrease
attained adult height.
Methods

We measured adult height in 943 of 1041 participants (90.6%) in the Childhood
Asthma Management Program; adult height was determined at a mean (±SD) age of
24.9±2.7 years. Starting at the age of 5 to 13 years, the participants had been randomly
assigned to receive 400 μg of budesonide, 16 mg of nedocromil, or placebo daily
for 4 to 6 years. We calculated differences in adult height for each active treatment
group, as compared with placebo, using multiple linear regression with adjustment
for demographic characteristics, asthma features, and height at trial entry.
Results

Mean adult height was 1.2 cm lower (95% confidence interval [CI], −1.9 to −0.5) in
the budesonide group than in the placebo group (P = 0.001) and was 0.2 cm lower
(95% CI, −0.9 to 0.5) in the nedocromil group than in the placebo group (P = 0.61).
A larger daily dose of inhaled glucocorticoid in the first 2 years was associated with
a lower adult height (−0.1 cm for each microgram per kilogram of body weight)
(P = 0.007). The reduction in adult height in the budesonide group as compared with
the placebo group was similar to that seen after 2 years of treatment (−1.3 cm; 95% CI,
−1.7 to −0.9). During the first 2 years, decreased growth velocity in the budesonide
group occurred primarily in prepubertal participants.
Conclusions

The initial decrease in attained height associated with the use of inhaled glucocorticoids in prepubertal children persisted as a reduction in adult height, although
the decrease was not progressive or cumulative. (Funded by the National Heart,
Lung, and Blood Institute and the National Center for Research Resources; CAMP
ClinicalTrials.gov number, NCT00000575.)
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I

nhaled glucocorticoids are the recommended therapy for persistent asthma in
children.1 In prepubertal children, however,
the use of inhaled glucocorticoids has been
shown to reduce growth velocity, resulting in a
linear growth reduction of 0.5 to 3.0 cm (approximately 1 cm on average) during the first few
years of therapy.2-4 This reduction has been reported for low-to-medium doses, but the degree
of reduction is dependent on the type of inhaled
glucocorticoid and the delivery method.5-9
Although growth velocity returns to normal
within a few years after the initiation of inhaled
glucocorticoid therapy (resulting in a deficit in
height that is not progressive), the long-term effect of the initial decrease in growth velocity on
attainment of adult height is still unclear.10-12
Retrospective, cross-sectional studies of the effect of inhaled glucocorticoid therapy in childhood on the attainment of adult height have had
conflicting results.10,13-15 In one small longitudinal study,11 there was no significant difference
between actual adult height and predicted adult
height in 142 participants who had received
budesonide in variable daily doses (mean, 427 μg)
during childhood for a mean of 9.2 years.
At the end of the Childhood Asthma Management Program (CAMP) clinical trial, we predicted
that the children receiving budesonide (Pulmicort
Turbuhaler, AstraZeneca) for a mean follow-up
of 4.3 years would attain the same adult height
as the children receiving nedocromil (Tilade,
Rhone-Poulenc Rorer) or placebo.2 It has been
hypothesized that children receiving inhaled
glucocorticoids grow for a longer period of time,
eventually catching up and having no long-term
effects from the decreased growth velocity seen
in the first few years of therapy.16 Thus, the effect of inhaled glucocorticoids on height has
often been characterized as growth retardation
rather than growth suppression. We later reported that the heights of the participants in the
budesonide group had not caught up with the
heights of participants in the placebo group after an additional 4.8 years of follow-up (total, 9.1
years), until the ages of 12 to 23 years.12 The
purpose of the current study was to continue the
height follow-up of the CAMP participants to
assess the effects of budesonide and nedocromil
on adult height.

n engl j med 367;10

Me thods
Participants and Study Design

From December 1993 through September 1995,
we randomly assigned 1041 children between the
ages of 5 and 13 years with mild-to-moderate
asthma to one of three study groups in the double-blind, placebo-controlled CAMP trial. In this
study, we compared the efficacy and safety of
200 μg of budesonide administered by means of
a dry-powder inhaler twice daily (400 μg per
day), 8 mg of nedocromil administered by means
of a metered-dose inhaler twice daily (16 mg per
day), and placebo. Albuterol was used for asthma
symptoms in all three groups. The design, methods, and results of the trial have been described
previously.2,17 At the end of the trial (mean followup, 4.3 years), the children were recruited into an
observational cohort, as described previously.12
During follow-up, the children were treated for
asthma by their primary care physicians under
advisement from the CAMP physicians on the basis of the guidelines of the National Asthma Education and Prevention Program.1 Height and weight
were measured every 6 months during the initial 4.5 years of observational follow-up and 1 to
2 times a year during the next 8 years. Adult height
was determined at a mean (±SD) age of 24.9±2.7
years. Tanner staging was performed annually
until the participants were 18 years of age or attained sexual maturity. (For details regarding the
trial design and phases of the observational follow-up, see Fig. S1 in the Supplementary Appendix, available with the full text of this article at
NEJM.org.) All study phases were approved by
the institutional review board at each study center. Participants who were 18 years of age or
older provided written informed consent; those
under the age of 18 years provided assent, with
written informed consent provided by their parents or guardians.
At each clinic visit, a trained technician used
a stadiometer (Harpenden 603, Holtain) to measure height, as described in the protocol (available
at NEJM.org), and investigators obtained an interim history of participants’ health and medication use. During the first 8 years of follow-up,
this information was supplemented with information obtained during telephone contacts that
were evenly spaced around the clinic visits.

nejm.org

september 6, 2012

905

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 16, 2014. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

On the basis of reported recommendations,18-21
adult height was defined as either the mean of all
measurements performed at the age of 18 years
or older for women and at the age of 20 years or
older for men or, if height was not measured at
these ages, the most recently obtained height
that was less than 1 cm greater than a height
obtained at least 1 year previously.
Statistical Analysis

We used a multiple linear regression model to compare mean height in the budesonide and nedocromil groups with that in the placebo group, with
adjustment for eight covariates at trial entry: age,
race or ethnic group, sex, clinic, height, duration
of asthma (<3 years, ≥3 to <7 years, or ≥7 years),
severity of asthma (moderate or mild), and presence or absence of skin-test reactivity. Data for
each participant were analyzed in the study group
to which the participant had been randomly assigned, regardless of subsequent asthma treatment. The adjusted mean height in each study
group was computed from the regression model
at the mean values for the covariates.22 To assess
the statistical significance of potential variations
in height differences between the budesonide or
nedocromil group and the placebo group across
subgroups defined by race or ethnic group, age at
trial entry, and duration of asthma at entry, we
added covariate interaction terms to the regression model. Although these post hoc interaction
tests may have a low statistical power for detecting variations in height effects across subgroups,
we wanted to examine the qualitative consistency
of the budesonide and nedocromil effects across
subgroups.
We used chi-square tests for categorical variables and t-tests for continuous variables to assess differences in baseline characteristics between participants for whom data regarding
adult height were missing and those for whom
such data were available. We used logistic-regression analysis to check for systematic differences
between participants with adult-height data and
those without such data with respect to studygroup distribution in subgroups, as defined by
the baseline covariates. Effects of missing data
on adult height were further addressed in sensitivity analyses with the use of two alternative
methods to impute missing adult height. In the
first method, we used a single imputation of
adult height on the basis of bone age obtained at
906
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the end of the trial and the equations of Tanner
et al.2,19 In the second method, we used multivariate multiple imputation with 13 imputations
from simulations of a Bayesian posterior predictive distribution of the missing data, using an
iterative Markov chain Monte Carlo method based
on the multivariate normal distribution provided
by Stata software.23 All eight covariates in the
model for difference in adult height were used
together with serial height measurements obtained 2 to 102 months after trial entry. The missing adult height data were assumed to be missing
completely at random. Additional sensitivity analy
ses were performed with the use of seven alternative definitions of adult height.
We used a linear regression model of height
in relation to age, using all available age–height
pairs for each participant in each 1-year age
span, to determine age-specific growth velocity
for each participant during the first 2 years of
the trial. We assessed study-group differences in
growth-velocity trends for participants between
the ages of 5 and 15 years separately for each sex
by means of a repeated-measures multiple linear
regression model,24 including an indicator variable for treatment, splines for each year of age,
and interaction terms for treatment according to
age. This analysis was also adjusted for the covariates used in the models of adult height. The
significance of study-group differences in velocity trends was determined on the basis of the
P value from an F-test of the simultaneous null
effects of the study-group indicator and all age
splines according to treatment interaction terms.
We performed a secondary analysis of adult height
in relation to the mean weight-adjusted dose of
daily inhaled glucocorticoids (in micrograms per
kilogram of body weight) during the first 2 years
of the trial, with adjustment for demographic
characteristics, status with respect to exposure
to cigarette smoke in utero, and total prednisone
dose throughout follow-up until adult height
was attained, as well as asthma features, physical development, and vitamin D sufficiency or
insufficiency at trial entry. The dose of inhaled
glucocorticoids and weight were assumed to be
constant over each reporting interval.
A two-sided P value of less than 0.05 was considered to indicate statistical significance, except
in interaction analyses, for which a P value of
less than 0.01 was considered to indicate significance. Statistical analyses were performed with
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2093 Patients were assessed for eligibility

1052 Were excluded owing
to asthma that was too severe
or too mild, other reasons for
ineligibility, nonadherence during
run-in period, or lack of interest

1041 Underwent randomization

311 Were assigned to receive
budesonide

312 Were assigned to receive
nedocromil

418 Were assigned to receive
placebo

30 Were lost to follow-up

27 Were lost to follow-up

41 Were lost to follow-up

281 Had measurement of adult height
271 Had measurement at age
≥18 yr (women) or
≥20 yr (men)
10 Grew <1 cm per year

285 Had measurement of adult height
274 Had measurement at age
≥18 yr (women) or
≥20 yr (men)
11 Grew <1 cm per year

377 Had measurement of adult height
368 Had measurement at age
≥18 yr (women) or
≥20 yr (men)
9 Grew <1 cm per year

Figure 1. Enrollment and Outcomes.

the use of Stata software, version 12 (StataCorp) the mean adult height in the nedocromil group
or SAS software, version 9.2 (SAS Institute).
(172.1 cm) was similar to that in the placebo
group (P = 0.61) (Table 1 and Fig. 2).25 The deficit
in adult height in the budesonide group, as comR e sult s
pared with the placebo group, was greater for
Adult Height
women (−1.8 cm, P = 0.001) than for men (−0.8,
We obtained measurements of adult height for P = 0.10), but the effect of budesonide on adult
943 of the original 1041 CAMP participants height did not vary significantly according to sex
(90.6%). Of these measurements, 96.8% were ob- (P = 0.10 for interaction) (Table 1). Although the
tained from women who were at least 18 years of deficit was greater for participants who were
age or men who were at least 20 years of age; younger at trial entry than for those who were
3.2% of measurements were the most recently older and greater for whites than for those of
obtained heights that were less than 1 cm greater other races or ethnic groups, the effect of
than a height obtained at least 1 year previously budesonide on adult height did not vary signifi(Fig. 1). Adult height was not known for 98 par- cantly according to the age at trial entry (P = 0.12
ticipants (9.4%): 35 female participants with a for interaction), race or ethnic group (P = 0.50 for
median age of 12 years (range, 8 to 17) and 63 interaction), or duration of asthma at trial entry
male participants with a median age of 14 years (P = 0.35 for interaction) (Table 1, and Table S1
(range, 7 to 19) at the last height measurement. in the Supplementary Appendix). The deficit in the
The adjusted mean adult height was 1.2 cm adjusted mean height in the budesonide group,
lower in the budesonide group than in the pla- as compared with the placebo group, was 1.3 cm
cebo group (171.1 cm vs. 172.3 cm, P = 0.001); (95% confidence interval [CI], −1.7 to −0.9) after
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Table 1. Adjusted Mean Adult Height among 943 Study Participants.*
Variable

Mean Adult Height
Budesonide
(N = 281)

Nedocromil
(N = 285)

Difference in Height
Placebo
(N = 377)

cm
All participants

Budesonide vs.
Placebo (95% CI)

P Value

cm

Nedocromil vs.
Placebo (95% CI)

P Value

cm

171.1

172.1

172.3

−1.2 (−1.9 to −0.5)

0.001

−0.2 (−0.9 to 0.5)

0.61

Female

162.8

163.9

164.6

−1.8 (−2.9 to −0.7)

0.001

−0.7 (−1.8 to 0.5)

0.26

Male

176.8

177.6

177.6

−0.8 (−1.8 to 0.2)

0.10

−0.0 (−0.9 to 0.9)

0.98

Sex

P value for interaction

0.10

0.49

Age at entry
5–8 yr

170.7

171.8

172.6

−1.9 (−3.2 to −0.6)

0.004

−0.8 (−2.1 to 0.5)

0.22

9–13 yr

171.4

172.4

171.9

−0.5 (−1.7 to 0.6)

0.37

0.5 (−0.8 to 1.6)

0.48

P value for interaction

0.12

0.15

* Mean values for adult height have been adjusted for age, race or ethnic group, sex, clinic, duration of asthma, asthma severity, presence or
absence of skin-test reactivity, and height at trial entry. In the analysis of mean adult height according to sex, 385 participants were female
and 558 were male. In the analysis of age at study entry, 489 participants were 5 to 8 years of age and 454 were 9 to 13 years of age.

At trial entry, data for participants for whom
2 years of treatment and 1.2 cm (95% CI, −2.0 to
−0.4) at the end of the CAMP trial and persisted measurements of adult height were not available
into adulthood without progressing further (−1.2 were similar to data for those with available measurements, except for the variable of the clinic site
cm; 95% CI, −1.9 to −0.5) (Fig. 2B).
(P = 0.002) (Table S2 in the Supplementary AppenGrowth Velocity
dix). There was no interaction between the study
Overall, age trends with respect to growth veloc- group and any of the baseline covariates, sugity in the budesonide and placebo groups differed gesting that the study-group comparison among
during the first 2 years of the trial for women the 943 participants with known adult height
(P = 0.007) and men (P<0.001) (Fig. S2 in the Sup- may reasonably be generalized to the entire
plementary Appendix). For both sexes, the differ- CAMP population.
ence in velocity reduction that was seen in the first
2 years of assigned treatment in the budesonide Effects of Glucocorticoid Dose
group, as compared with the placebo group, was During the trial period of 4 to 6 years, the mean
primarily among prepubertal participants (girls adjusted total doses of inhaled glucocorticoids were
5 to 10 years of age, P = 0.001; girls 11 to 15 years 636.1 mg in the budesonide group and 88.5 mg
of age, P = 0.54; boys 5 to 11 years of age, P<0.001; in the nedocromil group versus 109.4 mg in the
and boys 12 to 15 years of age, P = 0.57).
placebo group (P<0.001 and P = 0.14, respectively). During follow-up after the trial ended, the
Sensitivity Analyses
mean adjusted total doses were 381.0 mg in the
In sensitivity analyses performed to assess the budesonide group and 347.9 mg in the nedocropotential effect of missing adult heights, the re- mil group versus 355.0 mg in the placebo group
duction in adult height in the budesonide group (P = 0.55 and P = 0.87, respectively).
as compared with the placebo group was also calThe as-treated secondary analysis of the daily
culated with imputation of missing adult heights weight-adjusted dose of inhaled glucocorticoids
based on bone age at the end of the trial19 (−1.1 cm, during the first 2 years of the CAMP trial showed
P = 0.004) and multivariate multiple imputation that a larger daily dose was associated with a
(−1.2 cm, P = 0.002). The between-group differ- lower adult height (−0.1 cm for each microgram
ence in adjusted mean adult height remained nu- per kilogram, P = 0.007). In addition, lower adult
merically similar to that in the primary analysis height was associated with Hispanic ethnic group
and significant for all seven alternative defini- (P<0.001) and female sex (P<0.001), as well as
tions of adult height (Table 2).
a higher Tanner stage (P<0.001), lower height
908
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A Unadjusted Height Distribution
200

Budesonide

Placebo

190
180

Height (cm)

170
160
150
140
130
120
110
100
0

Trial entry

2 Yr

Trial end

Adult

Trial entry

2 Yr

Females

Trial end

Adult

Males

Budesonide vs. Placebo Height Difference
(cm)

B Height Difference, Budesonide vs. Placebo
3
2
1
0
−1
−2
−3

0

2

4

6

8

10

12

14

16

Years since Randomization
Mean Age (yr)

9

11

13

25

311
418

296
396

281
383

281
377

No. of Participants
Budesonide
Placebo

Figure 2. Effect of Budesonide on Adult Height.
Panel A shows Tukey’s box plots of unadjusted height distribution at trial entry (at the age of 5 to 13 years), at 2 years,
at the end of the trial, and at the time of adult-height determination for up to 311 participants receiving budesonide
and 418 receiving placebo, according to sex. The bottom and top of each box are the 25th and 75th percentiles of
the height distribution, respectively, and the horizontal line within the box is the median. The I bars indicate the
range of the distribution that is not extreme (i.e., within 1.5 interquartile ranges of the 25th and 75th percentiles of
the distribution), and the open circles show the extreme values in the height distribution. Panel B shows the adjusted
mean difference in height between the budesonide group and the placebo group during follow-up. The I bars indicate
95% confidence intervals. Means have been adjusted for age, race or ethnic group, sex, clinic, asthma severity, asthma
duration, and presence or absence of skin-test reactivity at trial entry. Mean values for times after time 0 (trial entry)
have also been adjusted for height at trial entry.

(P<0.001), greater body-mass index (P<0.001), lon- per milliliter, P = 0.004) at baseline. The cumulative
ger duration of asthma (P<0.001), skin-test reactiv- prednisone dose from trial entry until attainment
ity (P<0.001), and vitamin D insufficiency (≤30 ng of adult height did not affect adult height (P = 0.76).
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910
913
913
913
780
928
937

Minimum height at age ≥18 yr for women and ≥20 yr
for men

Maximum height at age ≥18 yr for women and ≥20 yr
for men

Most recent height at age ≥18 yr for women and ≥20
yr for men

n engl j med 367;10

Mean height at age ≥21 yr for women and ≥23 yr
for men

nejm.org

Height at time of growth of <1 cm/yr§

Mean height at age ≥21 yr for women and ≥23 yr
for men or at growth of <1 cm/yr
171.1

172.1

172.1

171.4

172.2

172.6

171.7

172.1

172.1

172.2

172.1

cm

Nedocromil

172.3

172.3

171.6

172.3

172.7

171.8

172.3

172.3

172.3

172.3

Placebo

−1.2 (−1.9 to −0.4)

−1.2 (−1.9 to −0.5)

−1.1 (−1.8 to −0.3)

−1.2 (−2.0 to −0.5)

−1.3 (−2.0 to −0.5)

−1.2 (−2.0 to −0.5)

−1.3 (−2.0 to −0.5)

−1.2 (−1.9 to −0.4)

−1.1 (−1.7 to −0.3)

−1.2 (−1.9 to −0.5)

cm

Budesonide vs.
Placebo
(95% CI)

0.002

0.001

0.01

0.001

0.001

0.001

0.001

0.002

0.004

0.001

P Value

−0.2 (−0.9 to 0.5)

−0.2 (−0.9 to 0.5)

−0.2 (−0.9 to 0.6)

−0.1 (−0.9 to 0.6)

−0.1 (−0.8 to 0.6)

−0.1 (−0.9 to 0.6)

−0.2 (−0.9 to 0.6)

−0.2 (−0.9 to 0.5)

−0.1 (−0.8 to 0.6)

−0.2 (−0.9 to 0.5)

cm

Nedocromil vs.
Placebo (95% CI)

Difference in Height

0.63

0.59

0.73

0.71

0.77

0.72

0.72

0.56

0.70

0.61

P Value

of

171.1

170.5

171.1

171.4

170.6

171.0

171.1

171.2

171.1

Budesonide

Mean Adult Height

n e w e ng l a n d j o u r na l

* Mean values for adult height have been adjusted for age, race or ethnic group, sex, clinic, duration of asthma, asthma severity, presence or absence of skin-test reactivity, and height at
trial entry.
† Projected adult height was calculated from the prediction equations of Tanner et al.,19 which use height, chronologic age, bone age, and (for girls) age at first menses.
‡ Adult height was imputed for the 98 participants for whom data regarding adult height were missing. The imputation analysis was completed with the use of multivariate normal regression of the available height data for the CAMP group (adult height for 943 participants and up to 21 serial height measurements performed 2 to 102 months after randomization
for 1041 participants) on age, race or ethnic group, sex, clinic, duration of asthma, asthma severity, presence or absence of skin-test reactivity, and height at trial entry, stratified according to study group.
§ In this category, adult height was defined as the chronologically later height in the most recent pair of height measurements that were performed at least 1 year apart and differed by
less than 1 cm.

913

Mean height at age ≥18 yr for women and ≥20 yr
for men

Alternative height definition

991
1041

Adult height or multiple-imputation height‡

943

Total No. of
Participants

Adult height or projected adult height†

Imputation strategy

Primary analysis

Variable

Table 2. Adjusted Mean Adult Height, According to the Imputation Strategy Used for Missing Data and Alternative Height Definitions.*
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Discussion
In an intention-to-treat analysis of the growthsuppressive effect of long-term inhaled glucocorticoid therapy for asthma initiated in children
between the ages of 5 and 13 years, we found
that the height deficit observed at 1 to 2 years
after treatment initiation persisted into adulthood, although the deficit was neither progressive nor cumulative. Our conclusion is based on a
randomized comparison of adult height, with
height data available for 91% of the CAMP cohort, with the use of recognized definitions of
adult height,18-21 and with consistent findings in
sensitivity analyses using imputation strategies
for missing data and alternative definitions of
adult height (Table 2). We found little evidence
that the 98 participants for whom data regarding
adult height were missing differed at trial entry
from the 943 participants with available data
(Table S2 in the Supplementary Appendix).
In contrast, the only other prospective longitudinal cohort study that followed patients into
adulthood11 was an open-label study, and by the
time the patients reached adulthood, only 15 of
the original controls were available, so the investigators recruited 51 healthy siblings of the patients with asthma to be controls. The investigators in that study based their conclusion of a lack
of long-term effect on height on the finding that
both controls and participants receiving budeso
nide attained predicted adult height rather than
on a randomized comparison of the adult heights
reached by the two groups.
The growth-velocity deficit that we observed
in the budesonide group, as compared with the
placebo group, during the first 2 years of treatment was primarily among prepubertal children
(Fig. S2 in the Supplementary Appendix). Our
ability to further disentangle the effects of duration of treatment, age at treatment, and puberty
status during treatment on growth velocity was
limited because of confounding. Nevertheless,
the effect on adult height of budesonide as compared with placebo was clearly demonstrated in
the CAMP population.
Two previous 1-year studies of beclomethasone
dipropionate also showed a greater reduction in
growth in prepubertal children than in pubertal
children.26,27 Like other studies in which prepubertal children received different doses of the
same inhaled glucocorticoids that have shown a
n engl j med 367;10

dose–response effect on growth,28,29 our study
showed a weight-based, dose-dependent effect in
the CAMP participants (Table S3 in the Supplementary Appendix).
We found that a longer time since asthma diagnosis at trial entry and atopy (any positive skin
test) were independent risk factors for shorter adult
height (Table S3 in the Supplementary Appendix).
Other investigators have reported an increased incidence of short stature in children with atopy and
asthma.30-32 One of these studies31 showed that
short stature was associated with an early onset
of asthma (before the age of 3 years), a finding
that is consistent with our data. However, atopyinduced growth retardation has been associated
with a delay in bone maturation and thus was
thought to be unlikely to affect adult height.32,33
Our results suggest that when asthma and atopy
impair growth, the deficit may persist into
adulthood.
We selected a daily dose of 400 μg of budeso
nide for the CAMP trial to ensure a therapeutic
effect in both children with mild asthma and
those with moderate asthma.2 Since then it has
been shown that daily administration of 200 μg of
budesonide by means of a dry-powder inhaler effectively controls asthma symptoms and reduces
exacerbations in children 5 to 11 years of age.3
Even at this lower dose, there was a reported mean
reduction of 1.0 cm in height during the first
2 years of therapy.3 Although the systemic effects
of inhaled glucocorticoids are dose-dependent,
they are also dependent on the therapeutic index
of the specific inhaled glucocorticoid and the
delivery device used.4-9 Thus, it seems prudent to
select inhaled glucocorticoids and devices with
higher therapeutic indexes and to use them in the
lowest effective doses in children with persistent
asthma.1,9
In conclusion, the reduction in growth seen in
the first few years of administration of inhaled
glucocorticoids in prepubertal children persists
as lowered adult height. However, in the information about inhaled glucocorticoids and their
side effects that is provided to parents, the potential effect on adult height must be balanced
against the large and well-established benefit of
these drugs in controlling persistent asthma. It
is appropriate to use the lowest effective dose for
symptom control in order to minimize concern
about the effects of inhaled glucocorticoids on
adult height.
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